Negara: Malaysia
Bahasa: Inggris
Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
PANTOPRAZOLE SODIUM SESQUIHYDRATE
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
PANTOPRAZOLE SODIUM SESQUIHYDRATE
2 x 7`s Tablets; 4 x 7`s Tablets
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ _ _ _ _ _ _ ___________________________________________________________________________________________________________________________ _ _ _ VENCID ENTERIC-COATED TABLET 40MG Pantoprazole 40mg (as Pantoprazole Sodium Sesquihydrate) WHAT IS IN THIS LEAFLET 1. What Vencid is used for 2. How Vencid works 3. Before you use Vencid 4. How to use Vencid 5. While you are using it 6. Side effects 7. Storage and Disposal of Vencid 8. Product description 9. Manufacturer and Product Registration Holder 10. Date of revision WHAT IS VENCID USED FOR It is used for the treatment of acid-related diseases of the stomach and intestine. Moderate to severe forms of gastro- oesophageal reflux (oesophagus inflammation accompanied by the regurgitating of stomach acid). _ _ Duodenal and stomach ulcer. An infection with a bacterium called _Helicobacter _ _pylori_ in patients with duodenal ulcers and stomach ulcers in combination with two antibiotics (Eradication therapy). _ _ Zollinger-Ellison syndrome and other conditions producing too much acid in the stomach. _ _ _ _ HOW VENCID WORKS Pantoprazole is a “selective proton pump inhibitor” something which reduces the amount of acid produced in your stomach. BEFORE YOU USE VENCID _- When must not to use it _ Do not take this medicine if you are: allergic (hypersensitivity) to the pantoprazole or any other ingredients in this medicine. taking atazanavir (a drug to treat HIV/ AIDS). in combination treatment with antibiotics, and have moderate to severe liver or kidney problems. _- Before you start use it _ Tell your doctor or pharmacist if you have: mild gastrointestinal complaints. unintentional weight loss. repeated vomiting. difficulty in swallowing. vomiting blood. anaemia. blood in stools severe liver problems. are pregnant or breast-feeding. _ _ Moreover, tell your doctor before taking this medicine, if you are due to have a specific blood test (Chromogranin A). _- Taki Baca dokumen lengkapnya
During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also, Chromogranin A (CgA) increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range. Pantoprazole is not indicated for mild gastrointestinal complaints, e.g, nervous stomach. dysphagia, haematemesis, anemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with pantoprazole may alleviate symptoms and delay diagnosis. Further investigation is to be considered if symptoms persist despite adequate treatment. In the case of combination therapy, the prescribing information for the respective drugs must be observed. Patient with severe hepatic impairment should be given 40mg of pantoprazole on alternate day. In patients with severe liver impairment, the liver enzymes should be monitored regularly during therapy, particularly on long-term use. Pantoprazole should be stopped if elevation of liver enzymes occurs. Pantoprazole, as other proton pump inhibitors, might be expected to increase the counts of bacteria normally present in the upper gastrointestinal tract. Treatment with pantoprazole may lead to slightly increased risk of gastrointestinal infections caused by bacteria (e.g. _ Salmonella, Campylobacter_ and ) REGULAR SURVEILLANCE: Patients on proton pump inhibitor treatment (particularly those treated for long term) should be kept under regular surveillance. SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE): Proton pump inhibitors are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, th Baca dokumen lengkapnya